THERAPY DOSSIER · th-a6aa4beddfbb

Monoclonal mouse anti-mouse interleukin-1beta IgG2a/k neutralising antibody (murine equivalent of canakinumab, donated by Novartis)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26358260 ↗2015Reported benefit

Targeting Interleukin-1beta Reduces Leukocyte Production After Acute Myocardial Infarction.

MouseIschaemia-reperfusionCardiacC57BL/6J wild type (n = 162), B6.129S7-Il1r1tm1Imx/J IL1R1 knockout (n = 28), apolipoprotein E-deficient B6.129P2-Apoetm1Unc/J (n = 24) and Nestin-GFP transgenic (n = 10)Femalen = 162 wild type, 28 IL1R1 knockout, 24 ApoE-deficient and 10…Subcutaneous10 mg/kg bodyweightTreatment initiated 2 h after induction of myocardial infarction

Model: Myocardial infarction by permanent ligation of the left anterior descending coronary artery; a separate cohort underwent ischaemia-reperfusion injury; parabiosis and lethally irradiated bone marrow chimera experiments

Interleukin-1beta released after myocardial infarction activated bone marrow haematopoietic stem cell proliferation, acting both directly on haematopoietic cells and indirectly through niche cells. Neutralising antibody begun 2 h after infarction reduced stem cell and progenitor proliferation, lowe…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…